Takeda winds down Theravance pact, culls partnered Crohn's program after PhII flops
Takeda revealed in its latest quarter filing that it’s ending a seven-year alliance with Theravance as the companies fold a program that flopped in Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.